US Patent 8008501 Quinoline compounds and their uses
Patent 8008501 was granted and assigned to Rigel Pharmaceuticals on August, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+514 characters)
Article
Patent abstract
The present invention provides quinoline compounds that inhibit the IgE receptor signaling cascade that leads to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE receptor signaling cascade.
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08008501 Quinoline compounds and their uses US Patent 8008501 Quinoline compounds and their uses
Infobox
Patent Number
0800850100
Patent Number
800850100
Edits on 29 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
080085010
Date of Patent
August 30, 2011
0Patent Application Number
109314810
Date Filed
September 1, 2004
0Patent Primary Examiner
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
080085010
Date of Patent
August 30, 2011
0Patent Application Number
109314810
Date Filed
September 1, 2004
0Patent Primary Examiner
Edits on 8 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08008501 Quinoline compounds and their uses
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08008501
Date of patent
August 30, 2011
Patent application number
10931481
Date Filed
September 1, 2004
Patent primary examiner
Find more entities like US Patent 8008501 Quinoline compounds and their uses
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
